The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6369-6373

  Jones, Clifford D ^a   Andrews, David M ^a   Barker, Andrew J ^a   Blades, Kevin ^a   Daunt, Paula ^a   East, Simon ^a   Geh, Catherine ^a   Graham, Mark A ^a   Johnson, Keith M ^a   Loddick, Sarah A ^a   McFarland, Heather M ^a   McGregor, Alexandra ^a   Moss, Louise ^a   Rudge, David A ^a   Simpson, Peter B ^a   Swain, Michael L ^a   Tam, Kin Y ^a   Tucker, Julie A ^a   Walker, Mike ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anti cancer; CDK; Cell cycle; Cyclin dependent kinase; Imidazole amide; Kinase; Kinase inhibitor

Indexed keywords

AZD 5438; AZD 5597; CYCLIN DEPENDENT KINASE INHIBITOR; IMIDAZOLE DERIVATIVE; PIPERAZINE; POTASSIUM CHANNEL HERG; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; RAT;

AMIDES; CELL LINE, TUMOR; CHEMISTRY, PHYSICAL; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 56249120210     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.102     Document Type: Article

References (18)

1. Sharma P.S., Sharma R., and Tyagi R. Curr. Cancer Drug Targets 8 (2008) 53
2. Cai D., Latham Jr. V.M., Zhang X., and Shapiro G.I. Cancer Res. 18 (2006) 9270
3. Goga A., Yang D., Tward A.D., Morgan D.O., and Bishop J.M. Nat. Med. 13 (2007) 820
4. Shapiro G.I. J. Clin. Oncol. 24 (2006) 1770
5. Anderson M., Andrews D.M., Barker A.J., Brassington C.A., Breed J., Byth K.F., Culshaw J.D., Finlay M.R.V., Fisher E., Gingell H.H.J., Green C.P., Heaton D.W., Nash I.A., Newcombe N.J., Oakes S.E., Pauptit R.A., Roberts A., Stanway J.J., Thomas A.P., Tucker J.A., and Weir H.M. Bioorg. Med. Chem. Lett. 18 (2008) 5487
6. Finlay M.R.V., Acton D.G., Andrews D.M., Barker A.J., Dennis M., Fisher E., Graham M.A., Green C.P., Heaton D.W., Karoutchi G., Loddick S.A., Morgentin R., Roberts A., Tucker J.A., and Weir H.M. Bioorg. Med. Chem. Lett. 18 (2008) 4442
7. Schroeder K., Neagle B., Trezise DJ., and Worley J. J. Biomol. Screen. 8 (2003) 50
8. Andrews, D.; Finlay, M. R.; Green, C.; Jones, C. PCT Int. Application WO2006-064251.
9. Andrews, D. M.; Barker, A. J.; Blades, K.; Byth, K. F.; Finlay, M. R. V.; Geh, C.; Green, C. P.; Johannsen, M.; Jones, C. D.; Walker, M.; Weir, H. M. Bioorg. Med. Chem. Lett., 2008, doi:10.1016/j.bmcl.2008.10.075.
10. 16 has been deposited in the Protein Data Bank with the deposition code 2w17 together with structure factors and detailed experimental conditions.
11. DeLano, W. L. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA; 2003. Available from: http://www.pymol.org.
12. Lawrie A.M., Noble M.E., Tunnah P., Brown N.R., Johnson L.N., and Endicott J.A. Nat. Struct. Biol. 4 (1997) 796
13. Legraverend M., Tunnah P., Noble M., Ducrot P., Ludwig O., Grierson D.S., Leost M., Meijer L., and Endicott J. J. Med. Chem. 43 (2000) 1282
14. CCP4 Acta Crystallogr. 1994, D50, 760.
15. AFITT, Peat T.S., Christopher J., and Schmidt K. Acta Crystallogr. A61 (2005) 165
16. Coot, Emsley P., and Cowtan K. Acta Crystallogr. D60 (2004) 2126
17. Refmac version 5.1.17, Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Acta Crystallogr. 1997, D53, 240.
18. + 438.